CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
-12.94%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(-0.55%)
Cap. Flow
+$221M
Cap. Flow
% of AUM
16.26%
Top 10 Holdings %
Top 10 Hldgs %
65.02%
Holding
35
New
4
Increased
13
Reduced
4
Closed
4
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$64M |
| 2 |
Celldex Therapeutics
CLDX
|
$58.1M |
| 3 |
Scholar Rock
SRRK
|
$25.6M |
| 4 |
Merus
MRUS
|
$25.2M |
| 5 |
Solid Biosciences
SLDB
|
$21.6M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$26.8M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$13.9M |
| 3 |
Alkermes
ALKS
|
$11.6M |
| 4 |
ABVX
Abivax
ABVX
|
$9.4M |
| 5 |
BBOT
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
|
$5.25M |
Sector Composition
| 1 | Healthcare | 99.43% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $188M | 13.87% | 4,472,840 +598,658 | +15% | +$25.2M |
|
2
Nuvalent
NUVL
$5.52B
| $132M | 9.69% | 1,855,000 +233,400 | +14% | +$16.6M |
|
3
Enliven Therapeutics
ELVN
$1.2B
| $92M | 6.78% | 4,675,000 +470,000 | +11% | +$9.25M |
|
|
4
Soleno Therapeutics
SLNO
$3.6B
| $82.2M | 6.05% | 1,150,000 -375,000 | -25% | -$26.8M |
|
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $78M | 5.75% | 2,325,000 -415,000 | -15% | -$13.9M |
|
|
6
Alkermes
ALKS
$4.78B
| $64.4M | 4.74% | 1,950,000 -350,000 | -15% | -$11.6M |
|
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $64M | 4.72% | +2,185,000 | New | +$64M |
|
8
Vaxcyte
PCVX
$4B
| $62.3M | 4.59% | 1,650,000 +25,000 | +2% | +$944K |
|
9
Vera Therapeutics
VERA
$1.38B
| $61.5M | 4.53% | 2,561,782 +603,182 | +31% | +$14.5M |
|
|
10
Celldex Therapeutics
CLDX
$1.47B
| $58.1M | 4.28% | +3,200,000 | New | +$58.1M |
|
|
11
Scholar Rock
SRRK
$3.14B
| $56.1M | 4.13% | 1,745,000 +795,000 | +84% | +$25.6M |
|
12
Cogent Biosciences
COGT
$1.69B
| $53.3M | 3.93% | 8,892,816 +2,011,187 | +29% | +$12M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $48.5M | 3.58% | 3,600,000 +1,200,000 | +50% | +$16.2M |
|
14
Nurix Therapeutics
NRIX
$714M
| $47.3M | 3.48% | 3,978,907 +978,907 | +33% | +$11.6M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $34M | 2.51% | 2,367,578 +149,153 | +7% | +$2.14M |
|
16
Spyre Therapeutics
SYRE
$996M
| $32.1M | 2.36% | 1,988,084 | – | – |
|
17
Pharvaris
PHVS
$1.39B
| $30M | 2.21% | 1,911,433 | – | – |
|
18
MindMed
MNMD
$676M
| $26.5M | 1.95% | 4,525,000 +216,575 | +5% | +$1.27M |
|
|
19
Solid Biosciences
SLDB
$427M
| $21.6M | 1.59% | +5,825,000 | New | +$21.6M |
|
|
DRUG
20
Bright Minds Biosciences
DRUG
$276M
| $18M | 1.33% | 500,000 | – | – |
|
21
Cardiff Oncology
CRDF
$140M
| $16.9M | 1.25% | 5,384,616 | – | – |
|
|
ORKA
22
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $14.6M | 1.07% | 1,419,714 | – | – |
|
23
Inhibikase Therapeutics
IKT
$134M
| $11.7M | 0.86% | 5,344,432 -580,568 | -10% | -$1.27M |
|
24
Oric Pharmaceuticals
ORIC
$994M
| $11.2M | 0.82% | 2,000,000 | – | – |
|
25
Apogee Therapeutics
APGE
$2.17B
| $10.8M | 0.8% | 290,000 | – | – |
|